Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma
Open Access
- 15 June 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (12) , 4388-4392
- https://doi.org/10.1158/1078-0432.ccr-04-2512
Abstract
Purpose: Testing the feasibility of using the serum low-molecular weight caldesmon (l-CaD) level as a serum marker for the presence of glioma.Keywords
This publication has 17 references indexed in Scilit:
- Differential expression of Hela‐type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cellsThe Journal of Pathology, 2005
- Classification actuelle des gliomesLa Presse Médicale, 2004
- Differential Expression of Splicing Variants of the Human Caldesmon Gene (CALD1) in Glioma Neovascularization versus Normal Brain MicrovasculatureThe American Journal of Pathology, 2004
- Vascular remodeling by intussusceptive angiogenesisCell and tissue research, 2003
- Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1pOncogene, 2002
- Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomasInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigusBritish Journal of Dermatology, 1999
- Intussusceptive Microvascular Growth in a Human Colon Adenocarcinoma Xenograft: A Novel Mechanism of Tumor AngiogenesisMicrovascular Research, 1996
- Inhibition of intracellular granule movement by microinjection of monoclonal antibodies against caldesmonCell Motility, 1991
- Caldesmon: Fragments, Sequence, and Domain MappingaAnnals of the New York Academy of Sciences, 1990